Targeting i 2-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours

Nature Communications

Volumn 5, Issue , 2014, Pages

  Jiang, Xiuli ^a   Cao, Yanan ^a   Li, Feng ^a   Su, Yutong ^a   Li, Yanli ^a   Peng, Ying ^a   Cheng, Yulong ^a   Zhang, Changxian ^b   Wang, Weiqing ^a   Ning, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLUCOSE; INSULIN; METHIONINE; PKF 115584; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; CTNNB1 PROTEIN, HUMAN; MEN1 PROTEIN, HUMAN; ONCOPROTEIN;

CELL ORGANELLE; ENDOCRINE DISRUPTOR; GENETIC ANALYSIS; MUTATION; PHYSIOLOGY; RODENT; SIGNALING; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE INACTIVATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULINOMA; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATIC NEUROENDOCRINE TUMOR; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL TIME; ANIMAL; C57BL MOUSE; DEFICIENCY; GENE DELETION; GENETICS; HYPERINSULINISM; KNOCKOUT MOUSE; METABOLISM; MORTALITY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PANCREAS TUMOR; PATHOLOGY; PERSONALIZED MEDICINE; PHOSPHORYLATION; SURVIVAL;

MUS;

ANIMALS; BETA CATENIN; CARCINOGENESIS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERINSULINISM; HYPOGLYCEMIA; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PRECISION MEDICINE; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84922734885     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6809     Document Type: Article

References (45)

1. Zhang, J. et al. Current understanding of the molecular biology of pancreatic neuroendocrine tumours. J. Natl Cancer Inst. 105, 1005-1017 (2013).
2. Halfdanarson, T. R., Rabe, K. G., Rubin, J. & Petersen, G. M. Pancreatic neuroendocrine tumours (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 19, 1727-1733 (2008).
3. Yao, J. C. et al. One hundred years after ''carcinoid'': epidemiology of and prognostic factors for neuroendocrine tumours in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063-3072 (2008).
4. Yao, J. C. et al. Population-based study of islet cell carcinoma. Ann. Surg. Oncol. 14, 3492-3500 (2007).
5. Larsson, C., Skogseid, B., Oberg, K., Nakamura, Y. & Nordenskjöld, M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332, 85-87 (1988).
6. Jiang, X. H. et al. MEN1 mutation analysis in Chinese patients with multiple endocrine neoplasia type 1. Endocr. Relat. Cancer 14, 1073-1079 (2007).
7. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumours. Science 331, 1199-1203 (2011).
8. Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207-218 (2005).
9. Thiel, A. T. et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 17, 148-159 (2010).
10. Huang, J. et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482, 542-546 (2012).
11. Cao, Y. et al. Hepatic menin recruits SIRT1 to control liver steatosis through histone deacetylation. J. Hepatol. 59, 1299-1306 (2013).
12. Matkar, S., Thiel, A. & Hua, X. Menin: a scaffold protein that controls gene expression and cell signalling. Trends Biochem. Sci. 38, 394-402 (2013).
13. Bertolino, P. et al. Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Res. 63, 4836-4841 (2003).
14. Yang, Y. et al. Reversal of preexisting hyperglycemia in diabetic mice by acute deletion of the Men1 gene. Proc. Natl Acad. Sci. USA 107, 20358-20363 (2010).
15. Cao, Y. et al. Nuclear-cytoplasmic shuttling of menin regulates nuclear translocation of beta-catenin. Mol. Cell Biol. 29, 477-5487 (2009).
16. Clevers, H. & Nusse, R. Wnt/b-catenin signalling and disease. Cell 149, 1192-1205 (2012).
17. Nelson, W. J. & Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303, 1483-1487 (2004).
18. Liu, C. et al. Control of beta-catenin phosphorylation/degradation by a dualkinase mechanism. Cell 108, 837-847 (2002).
19. Amit, S. et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16, 1066-1076 (2002).
20. Heller, R. S. et al. Expression of Wnt, Frizzled, sFRP, and DKK genes in adult human pancreas. Gene. Expr 11, 141-147 (2003).
21. Murtaugh, L. C., Law, A. C., Dor, Y. & Melton, D. A. Beta-catenin is essential for pancreatic acinar but not islet development. Development 132, 4663-4674 (2005).
22. Dessimoz, J., Bonnard, C., Huelsken, J. & Grapin-Botton, A. Pancreas-specific deletion of beta-catenin reveals Wnt-dependent and Wnt-independent functions during development. Curr. Biol. 15, 1677-1683 (2005).
23. Heiser, P. W., Lau, J., Taketo, M. M., Herrera, P. L. & Hebrok, M. Stabilization of beta-catenin impacts pancreas growth. Development 133, 2023-2032 (2006).
24. Rulifson, I. C. et al. Wnt signalling regulates pancreatic beta cell proliferation. Proc. Natl Acad. Sci. USA 104, 6247-6252 (2007).
25. Dabernat, S. et al. Lack of beta-catenin in early life induces abnormal glucose homeostasis in mice. Diabetologia 52, 1608-1617 (2009).
26. Herrera, P. L. Adult insulin-and glucagon-producing cells differentiate from two independent cell lineages. Development 127, 2317-2322 (2000).
27. Fontaniere, S. et al. Gene expression profiling in insulinomas of Men1 beta-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic beta-cell tumorigenesis. Endocr. Relat. Cancer 13, 1223-1236 (2006).
28. Wu, T., Zhang, X., Huang, X., Yang, Y. & Hua, X. Regulation of cyclin B2 expression and cell cycle G2/m transition by menin. J. Biol. Chem. 285, 18291-18300 (2010).
29. Lepourcelet, M. et al. Small-molecule antagonists of the oncogenic Tcf/betacatenin protein complex. Cancer Cell 5, 91-102 (2004).
30. Jansen, S. R., Van Ziel, A. M., Baarsma, H. A. & Gosens, R. {beta}-Catenin regulates airway smooth muscle contraction. Am. J. Physiol. Lung Cell Mol. Physiol. 299, L204-L214 (2010).
31. Gandhirajan, R. K. et al. Small molecule inhibitors of Wnt/beta-catenin/lef-1 signalling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 12, 326-335 (2010).
32. Sinnberg, T. et al. b-Catenin signalling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS ONE 6, e23429 (2011).
33. Sukhdeo, K. et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc. Natl Acad. Sci. USA 104, 7516-7521 (2007).
34. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumours. New Engl. J. Med. 364, 501-513 (2011).
35. Cao, Y. et al. Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat. Commun. 4, 2810 (2013).
36. Fraenkel, M. et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57, 945-957 (2008).
37. Wei, W., Chua, M. S., Grepper, S. & So, S. Small molecule antagonists of Tcf4/ beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int. J. Cancer 126, 2426-2436 (2010).
38. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumours. New Engl. J. Med. 364, 514-523 (2011).
39. Morris, L. G. et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat. Genet. 45, 253-261 (2013).
40. Tissier, F. et al. Mutations of beta-catenin in adrenocortical tumours: activation of the Wnt signalling pathway is a frequent event in both benign and malignant adrenocortical tumours. Cancer Res. 65, 7622-7627 (2005).
41. Doghman, M., Cazareth, J. & Lalli, E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J. Clin. Endocrinol. Metab. 93, 3222-3225 (2008).
42. Jiang, X. et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc. Natl Acad. Sci. USA 110, 12649-12654 (2013).
43. Liu, J. et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl Acad. Sci. USA 110, 20224-20229 (2013).
44. Wu, H. et al. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals. Nucl. Med. Commun. 34, 701-708 (2013).
45. Grodsky, G. M. & Fanska, R. E. The in vitro perfused pancreas. Methods Enzymol. 39, 364-372 (1975).